Company intelligence / Profile preview
CanSino Biologics Inc.
- Ownership
- Public · 688185
- Employees
- ~1494
- Development stage
- Commercial
Overview
CanSino has successfully commercialized several vaccines including Convidecia™ for COVID‑19—both injectable and inhaled forms—with global Phase III data showing ~66% efficacy against moderate COVID‑19 and >90% against severe cases. The company also markets approved meningococcal conjugate vaccines in China and has an expanding pipeline targeting over ten infectious diseases. Revenue growth remains strong with recent product launches.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Viral vector vaccines (adenovirus-based)Recombinant protein vaccinesmRNA and LNP technology
- Industry
- Biotech
Drug pipeline
56 assets55 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $2B
- Total revenue
- $138.1M
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on CanSino Biologics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CanSino Biologics Inc..